Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: New perspectives 2006

M. Kaufmann, G. Von minckwitz, H. D. Bear, A. Buzdar, P. Mcgale, H. Bonnefoi, M. Colleoni, C. Denkert, W. Eiermann, R. Jackesz, A. Makris, W. Miller, J. Y. Pierga, V. Semiglazov, A. Schneeweiss, R. Souchon, V. Stearns, M. Untch, S. Loibl

Research output: Contribution to journalArticle

Abstract

Neoadjuvant (primary systemic) treatment has become a standard option for primary operable disease for patients who are candidates for adjuvant systemic chemotherapy, irrespective of the size of the tumor. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2006 regarding neoadjuvant treatment for operable disease required updating. Therefore, a third international panel of representatives of a number of breast cancer clinical research groups was convened in September 2006 to update these recommendations. As part of this effort, data published to date were critically reviewed and indications for neoadjuvant treatment were newly defined.

Original languageEnglish
Pages (from-to)1927-1934
Number of pages8
JournalAnnals of Oncology
Volume18
Issue number12
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Neoadjuvant Therapy
Breast Neoplasms
Adjuvant Chemotherapy
Therapeutics
Research
Neoplasms

Keywords

  • Breast cancer
  • Neoadjuvant therapy
  • Recommendations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer : New perspectives 2006. / Kaufmann, M.; Von minckwitz, G.; Bear, H. D.; Buzdar, A.; Mcgale, P.; Bonnefoi, H.; Colleoni, M.; Denkert, C.; Eiermann, W.; Jackesz, R.; Makris, A.; Miller, W.; Pierga, J. Y.; Semiglazov, V.; Schneeweiss, A.; Souchon, R.; Stearns, V.; Untch, M.; Loibl, S.

In: Annals of Oncology, Vol. 18, No. 12, 12.2007, p. 1927-1934.

Research output: Contribution to journalArticle

Kaufmann, M, Von minckwitz, G, Bear, HD, Buzdar, A, Mcgale, P, Bonnefoi, H, Colleoni, M, Denkert, C, Eiermann, W, Jackesz, R, Makris, A, Miller, W, Pierga, JY, Semiglazov, V, Schneeweiss, A, Souchon, R, Stearns, V, Untch, M & Loibl, S 2007, 'Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: New perspectives 2006', Annals of Oncology, vol. 18, no. 12, pp. 1927-1934. https://doi.org/10.1093/annonc/mdm201
Kaufmann, M. ; Von minckwitz, G. ; Bear, H. D. ; Buzdar, A. ; Mcgale, P. ; Bonnefoi, H. ; Colleoni, M. ; Denkert, C. ; Eiermann, W. ; Jackesz, R. ; Makris, A. ; Miller, W. ; Pierga, J. Y. ; Semiglazov, V. ; Schneeweiss, A. ; Souchon, R. ; Stearns, V. ; Untch, M. ; Loibl, S. / Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer : New perspectives 2006. In: Annals of Oncology. 2007 ; Vol. 18, No. 12. pp. 1927-1934.
@article{fe2cd03d60a04b1b9827c83e386583b9,
title = "Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: New perspectives 2006",
abstract = "Neoadjuvant (primary systemic) treatment has become a standard option for primary operable disease for patients who are candidates for adjuvant systemic chemotherapy, irrespective of the size of the tumor. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2006 regarding neoadjuvant treatment for operable disease required updating. Therefore, a third international panel of representatives of a number of breast cancer clinical research groups was convened in September 2006 to update these recommendations. As part of this effort, data published to date were critically reviewed and indications for neoadjuvant treatment were newly defined.",
keywords = "Breast cancer, Neoadjuvant therapy, Recommendations",
author = "M. Kaufmann and {Von minckwitz}, G. and Bear, {H. D.} and A. Buzdar and P. Mcgale and H. Bonnefoi and M. Colleoni and C. Denkert and W. Eiermann and R. Jackesz and A. Makris and W. Miller and Pierga, {J. Y.} and V. Semiglazov and A. Schneeweiss and R. Souchon and V. Stearns and M. Untch and S. Loibl",
year = "2007",
month = "12",
doi = "10.1093/annonc/mdm201",
language = "English",
volume = "18",
pages = "1927--1934",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "12",

}

TY - JOUR

T1 - Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer

T2 - New perspectives 2006

AU - Kaufmann, M.

AU - Von minckwitz, G.

AU - Bear, H. D.

AU - Buzdar, A.

AU - Mcgale, P.

AU - Bonnefoi, H.

AU - Colleoni, M.

AU - Denkert, C.

AU - Eiermann, W.

AU - Jackesz, R.

AU - Makris, A.

AU - Miller, W.

AU - Pierga, J. Y.

AU - Semiglazov, V.

AU - Schneeweiss, A.

AU - Souchon, R.

AU - Stearns, V.

AU - Untch, M.

AU - Loibl, S.

PY - 2007/12

Y1 - 2007/12

N2 - Neoadjuvant (primary systemic) treatment has become a standard option for primary operable disease for patients who are candidates for adjuvant systemic chemotherapy, irrespective of the size of the tumor. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2006 regarding neoadjuvant treatment for operable disease required updating. Therefore, a third international panel of representatives of a number of breast cancer clinical research groups was convened in September 2006 to update these recommendations. As part of this effort, data published to date were critically reviewed and indications for neoadjuvant treatment were newly defined.

AB - Neoadjuvant (primary systemic) treatment has become a standard option for primary operable disease for patients who are candidates for adjuvant systemic chemotherapy, irrespective of the size of the tumor. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2006 regarding neoadjuvant treatment for operable disease required updating. Therefore, a third international panel of representatives of a number of breast cancer clinical research groups was convened in September 2006 to update these recommendations. As part of this effort, data published to date were critically reviewed and indications for neoadjuvant treatment were newly defined.

KW - Breast cancer

KW - Neoadjuvant therapy

KW - Recommendations

UR - http://www.scopus.com/inward/record.url?scp=37349009057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349009057&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdm201

DO - 10.1093/annonc/mdm201

M3 - Article

C2 - 17998286

AN - SCOPUS:37349009057

VL - 18

SP - 1927

EP - 1934

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

ER -